Brookfield Capital Partners to acquire Antylia Scientific for $1.4bn.

Synopsis

Brookfield Capital Partners, a global investment firm, agreed to acquire Antylia Scientific, a provider of biopharma, environmental and life sciences, for $1.4bn.

Principals

target

Antylia Scientific (ex Cole-parmer Instrument Company)

bidder

Brookfield Asset Management

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

ubs

HQ - Zurich

financial advisors

bidder

1217

Deals

£ 1,827.85 B

Total Value